BB Biotech
| BB Biotech AG
|
|
|---|---|
 |
|
| legal form | Corporation |
| ISIN | CH0038389992 |
| founding | November 9, 1993 |
| Seat |
Schaffhausen , Switzerland
|
| management | Erich Hunziker ( Chairman of the Board of Directors ) |
| sales | 241 million CHF (2019) |
| Branch | Investment company |
| Website | www.bbbiotech.com |
| As of December 31, 2019 | |
The BB Biotech AG is one of the world's largest biotechnology - holding companies .
The Swiss company primarily participates in listed companies that develop and market new drugs and where product development has already reached a more mature stage (i.e. drugs are already on the market and / or at least in phase II / III of clinical development).
BB Biotech relies on fundamental fundamental analysis and participates in biotechnology companies that have an attractive risk profile thanks to a solid science and technology base and sound financial structure.
The securities portfolio usually consists of four to six core holdings, which make up around seventy percent of the portfolio, as well as 15 to 20 other, smaller holdings. The proportion of unlisted companies should not exceed 10%.
The profit in the 2017 financial year was CHF 688 million .
history
BB Biotech was founded on November 9, 1993 in Schaffhausen (Switzerland). The company's bearer shares have been traded on the SWX Swiss Exchange since December 27, 1993, and on the Deutsche Börse in Frankfurt am Main since December 10, 1997, and from 2003 to June 2012 it was listed in the TecDAX , where it went from September Returned again in 2012 and June 2015. The shares have been listed on the Italian Nuovo Mercato since October 19, 2000, and in the Star segment ( TechStar ) since September 2005 .
structure
Erich Hunziker has been Chairman of the Board of Directors since 2013, and Clive A. Meanwell is Vice Chairman.
“Bellevue Asset Management AG” , which belongs to the Swiss Bellevue Group and is based in Küsnacht, ZH, was commissioned with the areas of fundamental analysis, portfolio management, marketing and administration . Investment decisions are delegated to “Asset Management BAB NV”, Curaçao (Netherlands Antilles).
In addition to BB Biotech, the companies of the BB Group also include the venture capital company "BB Biotechventures II". The equity capital in the individual biotech companies is held indirectly via the wholly-owned subsidiaries “Biotech Focus NV”, “Biotech Invest NV”, “Biotech Target NV”, “Biotech Growth NV”, each also based in Curaçao.
The majority of the shares are held in companies in the United States . These are divided into five to eight core holdings, of which Incyte and Celgene currently have the largest share in the portfolio. In addition, around two dozen smaller investments and up to 10% in unlisted companies ( private equity ) are held.
Web links
- Website of BB Biotech AG
Individual evidence
- ↑ Board of Directors. BB Biotech AG, accessed May 31, 2018 .
- ↑ BB Biotech key figures over time. In: finanzen.net. Retrieved April 6, 2020 .
- ↑ Annual Report 2017. (PDF; 293 kB) (No longer available online.) February 16, 2018, archived from the original on February 18, 2018 ; accessed on May 31, 2018 . Info: The archive link was inserted automatically and has not yet been checked. Please check the original and archive link according to the instructions and then remove this notice.
